We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

Journal Scan / Research · July 13, 2022

Atezolizumab With Neoadjuvant Anti-HER2 Therapy and Chemotherapy in HER2-Positive Early Breast Cancer

Journal of Clinical Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Clinical Oncology
Atezolizumab With Neoadjuvant Anti-Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial
J. Clin. Oncol 2022 Jun 28;[EPub Ahead of Print], J Huober, CH Barrios, N Niikura, M Jarząb, YC Chang, SL Huggins-Puhalla, J Pedrini, L Zhukova, V Graupner, D Eiger, V Henschel, N Gochitashvili, C Lambertini, E Restuccia, H Zhang

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading